What is changing in the rules, what it means for your product, your municipality or your project, and who here handles it. In English and Portuguese.
Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.
Environmental labelling requirements in France
Date of publication: 15/02/2023
On February 15, 2023, the European Commission initiated an infringement procedure against France regarding its requirement for the display of the Triman logo and the waste sorting instructions on products.
Ingredients: HYDROXYAPATITE (NANO)
Date of publication: 23/03/2023
On 23 March 2023, the SCCS published the final opinion on Hydroxyapatite (nano).
Ingredients: HYDROXYAPATITE (NANO)
Date of publication: 31/03/2022
On 11 January 2023, the SCCS published the preliminary opinion on Hydroxyapatite (nano). The deadline for comments was set for 1 March 2023.
Ingredients: RESORCINOL
The European Commission has shelved its plan to identify resorcinol as an endocrine disrupting SVHC under REACH Regulation.
Ingredients: TITANIUM DIOXIDE
Date of publication: 13/02/2023
France has appealed the EU General Court’s decision to annul the classification of titanium dioxide (TiO2) in certain powder forms as carcinogenic. The harmonized classification and labelling of Titanium Dioxide will continue to apply until the appeal has been decided.
Ingredients: PER- and POLYFLUOROALKYL substances (PFAS)
Date of publication: 07/02/2023
On February 7, 2023, the European Chemicals Agency (ECHA) announced its proposed restrictions on per- and polyfluoroalkyl substances (PFASs).
2022 EU Safety Gate Alerts
On 13 March 2023, the European Commission published its annual report on the Safety Gate, including 213 alerts related to cosmetic products.
Ingredients: HEXYL SALICYLATE
The European Commission has requested the Scientific Committee on Consumer Safety (SCCS) to assess the safety of Hexyl Salicylate as used in cosmetic products.
Ingredients: DIMETHYLTOLYLAMINE, TRIMETHYLBENZOYL DIPHENYLPHOSPHINE OXIDE
Proposed date of adoption: 20 days from publication in the OJEU
The European Commission notified the WTO of the draft text for the 21st Adaptation to Technical Progress (ATP) to the EU CLP Regulation. Two cosmetic nail modelling ingredients will be prohibited in EU.
Ingredients: ALPHA-ARBUTIN, BETA-ARBUTIN
Date of publication: 01/02/2023
On February 1, 2023, the Scientific Committee on Consumer Safety (SCCS) published its final opinion on the use of alpha-arbutin and betaa-arbutin in cosmetic products.
Ingredient: CYCLAMEN ALDEHYDE
Date of publication: 8 June 2026
The Scientific Committee on Consumer Safety (SCCS) has accepted a mandate to assess the safety of Cyclamen Aldehyde, following potential classification as a reproductive toxicant under the CLP Regulation.
Topic: OMNIBUS ACT IX - COSMETICS REGULATION
Date of publication: 28 July 2026
The European Commission notified the WTO about the draft Omnibus Act IX, proposing amendments to Annexes II, III, and V of the EU Cosmetics Regulation.
Topic: NEW RESTRICTIONS ON COSMETIC INGREDIENTS
Date of publication: 13 January 2026
The European Commission published Commission Regulation (EU) 2026/78, which brings new restrictions on several cosmetic ingredients that were classified as Carcinogenic, Mutagenic or Toxic for Reproduction (CMR).
Ingredient: TALC
Date of publication: January 2026
The United Kingdom (UK) Health and Safety Executive (HSE) has published a technical report concluding that Talc does not warrant carcinogenicity classification, diverging from ECHA's Risk Assessment Committee (RAC) opinion supporting Category 1B classification.
Four EUDAMED modules have been mandatory since 28 May 2026. Devices already on the market have until 27 November 2026. Who registers what, and what changed in Portugal.
From 25 February 2027, notified bodies under the MDR and IVDR must quote on defined information, keep to maximum timelines and publish their performance. What it changes for manufacturers.
Whether software is a medical device depends on what you say it is for, not on the code. The qualification test under the MDR and IVDR, updated for 2025 guidance.
Clinical data from an equivalent device can support your clinical evaluation, but the MDR sets a higher bar than the Directives did. The three characteristics, data access, and documentation.
One email when an area publishes, in the language you choose. Nothing else.
